Download PDF
CC BY 4.0 · Surg J (N Y) 2022; 08(03): e262-e265
DOI: 10.1055/s-0042-1756632
Original Article

Breast Carcinoma Receptor Expression in a Caribbean Population

Michael J. Ramdass 
1   Department of Clinical Surgical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago, West Indies
2   Department of Surgery, Port of Spain General Hospital, Port of Spain, Trinidad and Tobago
,
Joshua Gonzales
3   School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
,
Dale Maharaj 
2   Department of Surgery, Port of Spain General Hospital, Port of Spain, Trinidad and Tobago
,
Donald Simeon 
4   Caribbean Centre for Health Systems Research and Development, The University of the West Indies, St. Augustine, Trinidad and Tobago, West Indies
,
Shaheeba Barrow
5   Department of Pathology, Port of Spain General Hospital, Port of Spain, Trinidad and Tobago
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Trinidad and Tobago are islands in the Southern Caribbean with a unique mix of races within the population consisting of East Indian (EI) (37.6%), Afro-Caribbean (AC) (36.3%), mixed (24.2%), and Caucasian, Chinese, Lebanese, Syrian, Amerindian, and Spanish groups accounting for 1.9%. It makes it suitable for a comparison of breast carcinoma receptor expression within a fixed environment. This study included 257 women with an age range of 28 to 93 years (mean = 57.2, standard deviation = 15.0), peak age group of 51 to 60 consisting of 105 EI, 119 AC, and 33 mixed descent. Invasive ductal carcinoma accounted for 88%, invasive lobular 9.7%, and ductal carcinoma in situ 2.3%. The triple-negative rates were 24.8, 33.6, and 30.3% for EI, AC, and mixed races, respectively, with the Pearson's chi-square test revealing statistical significance for the AC versus EI (p < 0.001); AC versus mixed (p < 0.001); and EI versus mixed (p = 0.014) groups. The overall estrogen (ER), progesterone (PR), and human epidermal growth receptor (HER) expression negative rates were 52, 64, and 79%, respectively. Chi-square test of the following combinations: ER +/PR +/HER + ; ER +/PR +/HER − ; ER −/PR −/HER + ; ER +/PR −/HER + ; ER +/PR −/HER − ; ER −/PR +/HER + ; ER −/PR +/HER− revealed no statistical differences (p = 0.689).

Keywords

breast carcinoma - receptors - West Indian - Caribbean - East Indian - Afro-Caribbean


Publication History

Received: 23 May 2021

Accepted: 02 August 2022

Article published online:
19 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 2 Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev 2016; 25 (01) 16-27
    CrossrefPubMedGoogle Scholar
  • 3 Warner WA, Lee TY, Badal K. et al. Cancer incidence and mortality rates and trends in Trinidad and Tobago. BMC Cancer 2018; 18 (01) 712
    CrossrefPubMedGoogle Scholar
  • 4 Zhao S, Ma D, Xiao Y. et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist 2020; 25 (10) e1481-e1491
    CrossrefPubMedGoogle Scholar
  • 5 Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health 2015; 11 (02) 59-66
    CrossrefPubMedGoogle Scholar
  • 6 Viale G. The current state of breast cancer classification. Ann Oncol 2012; 23 (Suppl. 10) x207-x210
    CrossrefPubMedGoogle Scholar
  • 7 Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 2006; 3 (11) 621-632
    CrossrefPubMedGoogle Scholar
  • 8 Perou CM, Sørlie T, Eisen MB. et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747-752
    CrossrefPubMedGoogle Scholar
  • 9 Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22 (08) 1736-1747
    CrossrefPubMedGoogle Scholar
  • 10 Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med 2020; 8 (07) 499
    CrossrefPubMedGoogle Scholar
  • 11 Prat A, Pineda E, Adamo B. et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015; 24 (Suppl. 02) S26-S35
    CrossrefPubMedGoogle Scholar
  • 12 Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019; 321 (03) 288-300
    CrossrefPubMedGoogle Scholar
  • 13 Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 2019; 199: 30-57
    Google Scholar
  • 14 Diana A, Franzese E, Centonze S. et al. Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs. Curr Oncol Rep 2018; 20 (10) 76
    CrossrefPubMedGoogle Scholar
  • 15 Sengal AT, Haj Mukhtar NS, Vetter M. et al. Comparison of receptor-defined breast cancer subtypes between German and Sudanese women: a facility-based cohort study. J Glob Oncol 2018; 4: 1-12
    Google Scholar
  • 16 Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 2002; 74 (03) 199-211
    CrossrefPubMedGoogle Scholar
  • 17 Keegan THM, Chang ET, John EM. et al. Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004. Breast Cancer Res 2007; 9 (05) R62
    CrossrefPubMedGoogle Scholar
  • 18 Huo D, Hu H, Rhie SK. et al. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA Oncol 2017; 3 (12) 1654-1662
    CrossrefPubMedGoogle Scholar
  • 19 Abubakar M, Sung H, Bcr D. et al. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res 2018; 20 (01) 114
    CrossrefPubMedGoogle Scholar
  • 20 Howlader N, Altekruse SF, Li CI. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014; 106 (05) dju055
    CrossrefPubMedGoogle Scholar
  • 21 DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64 (01) 52-62
    CrossrefPubMedGoogle Scholar
  • 22 Wang JM, Wang J, Zhao HG, Liu TT, Wang FY. Reproductive risk factors associated with breast cancer molecular subtypes among young women in Northern China. BioMed Res Int 2020; 2020: 5931529
    PubMedGoogle Scholar
  • 23 Hadgu E, Seifu D, Tigneh W. et al. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health 2018; 18 (01) 40
    CrossrefPubMedGoogle Scholar
  • 24 Huo D, Ikpatt F, Khramtsov A. et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009; 27 (27) 4515-4521
    CrossrefPubMedGoogle Scholar
  • 25 Naraynsingh V, Hariharan S, Dan D, Bhola S, Bhola S, Nagee K. Trends in breast cancer mortality in Trinidad and Tobago–a 35-year study. Cancer Epidemiol 2010; 34 (01) 20-23
    CrossrefPubMedGoogle Scholar
  • 26 Samaroo K, Hosein A, Olivier LK, Ali J. Breast cancer in the Caribbean. Cureus 2021; 13 (08) e17042
    PubMedGoogle Scholar
  • 27 Badal K, Ali R, Warner WA. et al. Factors associated with breast cancer recurrence and survival at Sangre Grande Hospital, Trinidad. Cancer Causes Control 2021; 32 (07) 763-772
    CrossrefPubMedGoogle Scholar
  • 28 D Joseph M, Thorpe L, Annandsingh C. et al. Breast cancer diagnosis from screening in Trinidad and Tobago: opportunities for cancer prevention. J Immigr Minor Health 2014; 16 (03) 409-415
    PubMedGoogle Scholar
  • 29 Warner WA, Morrison RL, Lee TY. et al. Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. Cancer Med 2015; 4 (11) 1742-1753
    CrossrefPubMedGoogle Scholar
  • 30 Camacho-Rivera M, Ragin C, Roach V, Kalwar T, Taioli E. Breast cancer clinical characteristics and outcomes in Trinidad and Tobago. J Immigr Minor Health 2015; 17 (03) 765-772
    CrossrefPubMedGoogle Scholar